Nasdaq-listed medical device technology firm BioSig Technologies has completed its merger with Streamex Exchange Corporation, a blockchain-focused company, marking a significant shift towards real-world asset (RWA) tokenization. The merger, finalized on July 8, 2025, aims to leverage blockchain technology to enhance liquidity and transparency in the $142 trillion global commodities market.
To support this new direction, BioSig and Streamex have secured up to $1.1 billion in growth financing from a leading institutional investor. The financing package includes the sale of $100 million in senior secured convertible notes and an equity line of credit of up to $1 billion. The debentures will be convertible into shares of BioSig's common stock. The first $75 million of the funding is expected to be deployed by October 7, 2025. The remaining funds will be deployed over the next 24 months to support ongoing operations, research and development, and strategic acquisitions. Cantor Fitzgerald, Clear Street, and Needham & Company acted as placement agents for the financing, with CIBC World Markets serving as a strategic advisor.
The primary focus of this collaboration is to establish a gold-backed treasury management strategy powered by the Solana blockchain. BioSig and Streamex aim to bring a portion of the $142 trillion commodities market on-chain, starting with gold. BioSig's announcement follows a merger with Streamex that saw the company become one of Nasdaq's largest gold bullion holders. According to Streamex, RWA tokenization is a major ecosystem in the evolving market, and gold tokenization has the potential to dwarf Bitcoin (BTC) as traditional financial institutions embrace tokenized assets exposure.
Henry McPhie, CEO of BioSig Technologies and co-founder of Streamex, emphasized that combining physical gold with blockchain innovation creates a company grounded in a trusted store of value, enabling a scalable, high-return business model through tokenization. McPhie noted that Streamex aims to use its balance sheet capital to seed liquidity into creating gold and structured product gold-related tokens, a slightly different approach than existing players like Paxos Gold and Tether Gold. The company plans to purchase gold and gold-like assets, tokenize them, and bring them to market. BioSig expects to generate revenue from its tokenized gold fund through origination fees, tokenization fees, secondary trading fees, and spread income, with the first tokenized gold asset expected by early 2026.
The merger also brings changes to the leadership structure. Henry McPhie has taken the reins as CEO and joined the board of directors, while Morgan Lekstrom now serves as Chairman. Former BioSig CEO Anthony Amato remains on the board to support the integration of the two companies.
The broader RWA tokenization market is forecast to grow to $16 trillion by 2030, offering a massive opportunity for early movers. By offering programmable, liquid, and transparent representations of real-world commodities, BioSig hopes to become a dominant player in this emerging space.
